Jobs
-
Submit poster abstracts by August 19, 2012 at the INTFG submission site. Submissions on any inhalation or nasal drug technology topic are welcome. More information. Read more . . .
-
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis.… Read more . . .
-
Entries submitted to several student inhaler and medical device design contests over the past year envision some radical changes in inhaler design. These concepts, created by students who range in age from primary school through… Read more . . .
-
Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones… Read more . . .
-
Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection… Read more . . .
-
According to Insmed, the company has decided to focus on European and Canadian studies of its Arikace liposomal amikacin for inhalation and to put a US Phase 3 study on the back burner. The CLEAR-108… Read more . . .
-
The TOBI Podhaler has been named a bronze winner in the General Hospital Devices and Therapeutics Products division of the Medical Design Excellence Awards presented by UBM Canon and MD+DI. The inhaler, which is marketed… Read more . . .
-
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Almirall’s Eklira Genuair aclidinium DPI for the treatment of COPD. The Genuair… Read more . . .
-
Mylan has announced that its subsidiary Mylan Specialty (formerly Dey Pharma) has reached an agreement with Sunovion Pharmaceuticals (formerly Sepracor) in which Sunovion “has acknowledged that two Mylan patents are valid, enforceable and infringed by… Read more . . .
-
According to Sun Pharma, the FDA has approved an Abbreviated New Drug Application (ANDA) for a generic version of azelastine nasal spray submitted by a Sun subsidiary. Sun notes that the US sales of azelastine… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK